Business Context and Reporting Period
Company: Theravance Biopharma, Inc. (TBPH)
Filing Type: Form 8-K (Current Report)
Date of Report: June 28, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with Zymeworks Inc. ("Parent").
Theravance Biopharma, Inc. has agreed to be acquired by Zymeworks Inc. in a transaction structured as a merger. Upon closing, Theravance will become a wholly-owned subsidiary of Zymeworks. The transaction is expected to close in the second half of 2026, subject to shareholder approval and regulatory conditions.
Key Financial Metrics and Transaction Terms
This filing details the terms of the proposed merger rather than historical financial performance. Key financial terms include:
- Per Share Cash Consideration: $17.00 in cash for each outstanding ordinary share.
- Contingent Value Rights (CVRs): Each share also receives one CVR, entitling holders to potential future payments based on the performance of the asset "ampreloxetine."
- CVR Payment Structure:
- 80% of net proceeds from any license or divestiture of ampreloxetine within 10 years.
- $50 million milestone payment upon the first commercial sale of ampreloxetine in specified markets (U.S., UK, Spain, France, Germany, Italy).
- 10% of net sales royalties on ampreloxetine.
- Termination Fees:
- Company Fee: $32,515,000 payable by Theravance if the deal is terminated due to a Superior Proposal or Change of Recommendation.
- Reverse Termination Fee: $32,515,000 payable by Zymeworks if the deal fails due to unmet HSR Act Clearance conditions.
- Financing: Zymeworks has obtained a debt financing commitment from OMERS Life Sciences; the merger is not subject to a financing condition.
Historical Financials: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for Theravance Biopharma.
Material Changes and Conditions
The primary material change is the proposed change of control. The transaction is subject to the following closing conditions:
- Approval by holders of at least two-thirds of the Ordinary Shares present and voting at an extraordinary general meeting.
- Expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act Clearance).
- Absence of legal restraints preventing the merger.
- Absence of a continuing material adverse effect on the Company.
The Merger Agreement includes a termination date of December 28, 2026, which may be extended automatically for two three-month periods if certain conditions are met.
Guidance, Outlook, and Risks
Outlook: The parties expect the merger to close in the second half of 2026. A preliminary proxy statement will be filed promptly.
Risks and Contingencies:
- CVR Uncertainty: There is no assurance that a license for ampreloxetine will be executed, that commercial sales will occur, or that any CVR payments will be made.
- Shareholder Approval: The transaction requires a two-thirds vote, which may not be obtained.
- Regulatory Approval: Failure to obtain HSR Act Clearance could result in termination and a reverse termination fee.
- Operational Risks: Risks include potential litigation, employee retention issues, and disruptions to business operations during the pendency of the transaction.
- Forward-Looking Statements: Actual results may differ materially from expectations due to risks inherent in drug development and the M&A process.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and CVR Agreement in the definitive proxy statement (Schedule 14A).
- Confirm the outcome of the shareholder vote required for the two-thirds approval threshold.
- Monitor the status of HSR Act Clearance and any other regulatory approvals.
- Review the development status and commercial potential of ampreloxetine to assess the likelihood of CVR payments.
- Check for any competing acquisition proposals or "Superior Proposals" that could trigger a change of recommendation or termination fee.
- Review the definitive proxy statement for details on the treatment of outstanding options, RSUs, and PSUs.